Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunogenetic study in hypertrophic cardiomyopathy].

P Gregor1, E Ivasková, H Sajdlová

  • 12. interní klinika 3. lékarské fakulty Univerzity Karlovy, Praha.

Vnitrni Lekarstvi
|May 1, 1992
PubMed
Summary

Human Leukocyte Antigen (HLA) B21 is linked to a higher risk of severe hypertrophic cardiomyopathy, particularly obstructive forms and advanced myocardial hypertrophy. This finding aids in diagnosing atypical disease presentations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pacemaker reprogramming rarely needed after device replacement.

Herz·2017
Same author

THA and TKA in patients with cardiovascular disease: What makes the risk of perioperative bleeding?

Bratislavske lekarske listy·2017
Same author

Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions.

European heart journal. Cardiovascular pharmacotherapy·2016
Same author

Risk comparison of bleeding and ischemic perioperative complications after acute and elective orthopedic surgery in patients with cardiovascular disease.

Archives of orthopaedic and trauma surgery·2016
Same author

Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing non-cardiac surgery. Focus on antithrombotic medication. The PRAGUE-14 registry.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2014
Same author

Genetic testing in the management of relatives of patients with hypertrophic cardiomyopathy.

Folia biologica·2014

Area of Science:

  • Immunogenetics
  • Cardiology

Context:

  • Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease.
  • Previous studies on Human Leukocyte Antigen (HLA) associations with HCM have yielded controversial results.
  • A need exists for studies with larger patient cohorts and consideration of disease phenotypes.

Purpose:

  • To investigate the association between specific HLA antigens and hypertrophic cardiomyopathy.
  • To analyze HLA antigen prevalence across different functional and morphological forms of HCM.

Summary:

  • This study assessed 60 HLA class 1 and 2 antigens in 117 HCM patients.
  • A significantly higher prevalence of HLA-B21 was observed in patients with obstructive HCM and myocardial hypertrophy exceeding 30 mm.
  • HLA antigen examination may assist in diagnosing atypical HCM cases.

Related Experiment Videos

Impact:

  • Identifies HLA-B21 as a potential biomarker for increased risk of severe, early-onset hypertrophic cardiomyopathy.
  • Highlights the utility of HLA antigen assessment in the comprehensive evaluation of specific HCM subtypes.
  • Contributes to understanding the immunogenetic underpinnings of hypertrophic cardiomyopathy.